By Byron Kaye SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight ...

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre screening, widening its reach before patients ever enter a sleep lab. Recent FDA approvals are supporting ResMed's role ...

Shares of ResMed Inc. RMD rallied 1.72% to $271.63 Friday, on what proved to be an all-around great trading session for the ...

We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.86, with a ...

Air Voel, a fast-growing Canadian provider of sleep therapy and respiratory care equipment, has announced the expansion ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

Analysts estimate that ResMed will report an earnings per share (EPS) of $2.71. The announcement from ResMed is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

ResMed’s fourth quarter performance drew a positive market reaction, with management attributing the outperformance to strong global demand for its masks and devices, as well as continued growth in ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

When Philips first began its massive recall of more than 5 million CPAP and BiPAP machines and other ventilators in mid-2021, its competitor ResMed swooped in to fill the void left behind—seemingly ...